Annual Report

Overview

The report highlights FY25 revenue of INR 1,789 million and an EBITDA margin of approximately 29%. It records EU GMP approval for the oncology unit, enabling exports and market expansion. The company also allocated INR 35,00,000 to CSR initiatives focused on healthcare facilities and underserved communities.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024-2025
Period: 1 April 2024 – 31 March 2025
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services